scholarly journals The Use of Intravenous Neostigmine in Palliation of Severe Ileus

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Pashtoon Murtaza Kasi

Neostigmine is a parasympathomimetic drug that acts as a reversible acetylcholinesterase inhibitor. Clinically it is used in patients with acute colonic pseudo-obstruction (ACPO or Ogilvie’s syndrome, which is a gastrointestinal motility disorder characterized by marked dilatation of the colon in the absence of mechanical obstruction), postoperative ileus, urinary retention, myasthenia gravis, and in anesthesia to reverse the effects of nondepolarizing muscle relaxants. Both bolus and infusion are noted to be effective and lead to prompt evacuation of flatus or stool with a reduction in abdominal distention on physical examination. Median duration is noted to be 4–30 minutes in some trials. Here we present our experience of using 2 mg of intravenous neostigmine to help relieve the severe abdominal distention and ileus in a patient with severe fecal impaction when all conservative measures had been futile. The most frequent side effect of the drug is abdominal pain/cramping, which was noted in our patient as well. Other complications include bradycardia which is very infrequently symptomatic to require atropine. Overall, the drug is a simple, safe, and effective strategy; and as pointed out in the previous studies, the drug appears to be underused in patients who do not have a true contraindication to its use.

2009 ◽  
Author(s):  
Idoris Cordero Escobar ◽  
Javier Espinaco Vald��s ◽  
Angela R Gutierrez Rojas ◽  
Nicolas Parisi L��pez ◽  
Rosa E Jimenez

2007 ◽  
Author(s):  
I Cordero Escobar ◽  
J Espinaco Vald��s ◽  
AR Gutierrez Rojas ◽  
RE Jimenez Paneca ◽  
N Parisi L��pez

1998 ◽  
Vol 86 (Supplement) ◽  
pp. 457S
Author(s):  
S. Hashimoto ◽  
O. Shibata ◽  
A. Tsuda ◽  
S. Iwanaga ◽  
T. Makita ◽  
...  

2007 ◽  
Vol 85 (8) ◽  
pp. 774-782 ◽  
Author(s):  
S.B. Bhatt ◽  
A. Amann ◽  
V. Nigrovic

Nondepolarizing muscle relaxants (MRs) display an inverse onset–potency relationship, that is, less potent MRs display a more rapid onset. We have conducted the current investigation to estimate the impact of variable pharmacokinetic or pharmacodynamic properties of the MRs on potency and onset time, and on the onset–potency relationship. Using a model of neuromuscular transmission, we changed either the affinity of MRs for the postsynaptic receptors or the pharmacokinetic properties of the MRs. The elimination rate constant, k10, which defines the systemic clearance, was assigned one of 9 values and the transport rate constant, k12, one of 5 values. The transport rate constant into the effect compartment was constant (ke1 = 0.2 min–1). Only one parameter was altered at a time. With constant pharmacokinetics, a 100-fold decrease in affinity caused a proportional decrease in potency, but little change (0.02 min) in onset time. With constant affinity, increasing the clearance from 1 to 250 mL·kg–1·min–1 shortened the onset time from 7.2 to 0.7 min and decreased the potency 12-fold. In a double logarithmic plot, the onset–potency relationship was linear. Lesser affinities produce a nearly parallel rightward shift of the regression lines. The inverse onset–potency relationship may be explained by the pharmacokinetic factors producing changes in both the potency and onset times.


Sign in / Sign up

Export Citation Format

Share Document